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Abstract
Background: The purpose of this study was to determine the incidence, risk factors and prognostic impact of anaemia 
and thrombocytopenia in patients with bone metastases (BM) from prostate cancer.
Methods: Retrospective cohort study including 51 consecutive patients treated at a community hospital. Twenty-nine 
patients (57%) received taxotere after diagnosis of BM.
Results: Haemoglobin (Hb) ≤ 12.0 g/dL at BM detection was associated with shorter overall survival. During follow-up, 
25 patients (49%) experienced episodes with Hb < 10 g/dL unrelated to side effects of cancer therapy. Fifteen patients 
required red blood cell transfusion. Median time from diagnosis of BM to Hb < 10 g/dL was 23 months. Median survival 
from Hb < 10 g/dL was 5.4 months. There was no factor predicting for Hb < 10 g/dL. Five patients (10%) developed 
thrombocyte (Trc) count <50 × 109/L. All of these had previously received blood transfusion. Median interval from Hb < 
10 g/dL to Trc < 50 × 109/L was 2.5 months. Survival after thrombocytopenia was short (3 weeks to 4 months). 
Haematuria and subdural haematoma were among the causes of death.
Conclusions: We found high rates of significant bone marrow failure in treatment-refractory patients. Both Hb < 10 g/
dL and Trc < 50 × 109/L predict for unfavourable survival.
Background
Bone metastasis is a common complication in patients
with advanced stage prostate cancer and might even be
found already at first clinical diagnosis [1,2]. Depending
on the extent of spread, bone marrow function might
become compromised, resulting in anaemia und throm-
bocytopenia [3,4]. Prognosis after onset of anaemia und
thrombocytopenia is not well described in the literature.
In addition, factors predicting for these complications are
poorly understood. To study the incidence, outcome and
risk factors for anaemia and thrombocytopenia in men
with prostate cancer and skeletal metastases, a retrospec-
tive cohort study was performed.
Methods
A retrospective analysis, which included all patients with
prostate cancer and bone metastases treated at the
authors' institution during 2007 and 2008, was per-
formed. The authors' institution is a community hospital
in rural Norway, which is the only oncology care provider
and services the complete population of the county, i.e.
approximately 236,000 inhabitants. Thus, the 51 consec-
utive patients included in this study represent an unse-
lected population. Follow-up information was available in
all patients. Temporary anaemia, leuko- and thrombocy-
topenia episodes might result from chemotherapy or
radioisotope toxicity, necessitating for example chemo-
therapy dose reduction. Such toxicity is reversible and
not expected to predict short survival. The present analy-
sis did not include reversible events in patients who
received chemotherapy or radioisotopes at the time of the
event. It is focused on anaemia and thrombocytopenia
resulting from disease progression. The cut-off for low
Hb was set at 10.0 g/dL as patients with higher values are
not expected to receive red blood cell transfusion.
Regarding Trc, 50 × 109/L was chosen as higher values
will not result in bleeding complications. The normal
range for haemoglobin (Hb) was 13.4-17.0 g/dL. The nor-
mal range for thrombocytes (Trc) was 130-400 × 109/L.
We used the Kaplan-Meier method to generate actuarial
survival curves. Patients without event were censored at
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last clinical follow-up. Survival was calculated from the
date of imaging diagnosis of bone metastases (typically by
isotope bone scan) or from development of Hb < 10 g/dL.
Survival curves were compared with the log rank test.
Wilcoxon- and Kruskal-Wallis-tests were used to com-
pare the baseline characteristics between different
groups. A p-value ≤ 0.05 was considered statistically sig-
nificant.
Results
The patient characteristics and length of follow-up are
shown in Table 1. Treatment consisted of different types
of androgen suppression regimens incl. steroids and palli-
ative external beam radiotherapy in patients with bone
pain, metastatic spinal cord compression or surgically
stabilized pathological fractures. Administration of other
treatments is also shown in Table 1. Twenty-nine patients
(57%) received taxotere after diagnosis of bone metasta-
ses and 7 of these also proceeded to second-line treat-
ment with mitoxantrone. The initial number of bone
metastases on radioisotope bone scan was significantly
higher in patients with synchronous presentation (25%
with up to 10 foci, 55% with more than 10 foci and 20%
with super scan) compared to metachronous presenta-
tion (52% with up to 10 foci, 45% with more than 10 foci
and 3% with super scan), p = 0.05. Patients with synchro-
nous presentation also had significantly higher median
prostate-specific antigen (PSA) value, p < 0.01 (Table 1).
No other significant differences in baseline characteris-
tics were found between these two groups.
All baseline characteristics shown in Table 1 were
examined for their prognostic impact. Patients with bone
metastases at initial diagnosis had a 2-year survival rate
of 61% versus 55% in those with metachronous bone
metastases (Figure 1, p = 0.6). PSA level significantly
influenced survival, but only in patients with metachro-
nous bone metastases. The 2-year survival rate was 30%
in patients with PSA ≥ 21 μg/L at the time of bone metas-
tases detection versus 71% in those with lower PSA, p <
0.01. While Hb at the time of bone metastases detection
was not significant when using the median value as cut-
off, a strong trend for correlation between Hb ≤ 12.0 g/dL
and short survival was found, p = 0.03 (when correcting
for the fact that 2 tests were performed, i.e. median Hb
and Hb ≤ 12.0 g/dL, the Bonferroni correction requires p
≤ 0.025). Four of 5 patients with Hb ≤ 12.0 g/dL died
within 18 months. None of the other factors significantly
correlated with survival. Given these results, a multivari-
ate analysis did not appear appropriate. Among the treat-
ment-related factors, only the administration of
chemotherapy significantly influenced survival. The 2-
year rate was 68% in chemotherapy-treated patients ver-
sus 41% in others, p = 0.04.
Overall, 25 patients (49%) experienced episodes with
Hb < 10 g/dL in the absence of chemotherapy and radio-
isotope injection, typically as a sign of disease progres-
sion indicating failure of the current treatment line.
Fifteen of these patients (60%) required red blood cell
transfusion (29% of all patients in the study). Erythropoi-
esis stimulating agents were not used. The median time
from diagnosis of bone metastases to Hb < 10 g/dL was
approximately 2 years (Figure 2). Median survival from
Hb < 10 g/dL was 5.4 months (Figure 3). There was no
factor predicting for episodes with Hb < 10 g/dL. Inter-
estingly, patients having had Hb below median at diagno-
sis of bone metastases were not at increased risk of
developing Hb < 10 g/dL during the course of disease.
Their risk was 43% as compared to 59% in patients with
Hb above median. Figure 4 shows that patients who
maintained Hb ≥ 10 g/dL during follow-up had signifi-
cantly longer survival from first diagnosis of bone metas-
tases as compared to patients who developed Hb < 10 g/
dL. Five patients (10%) developed episodes with Trc < 50
× 109/L. All of these had previously experienced Hb < 10
g/dL and received red blood cell transfusion. Thus, 5 of
15 patients (33%) who had required transfusion also
developed severe thrombocytopenia. The interval from
Hb < 10 g/dL to Trc < 50 × 109/L was 1-4 months, median
2.5 months. The outcome of these 5 patients is shown in
Table 2. In spite of repeat platelet transfusion survival was
short, ranging from 3 weeks to 4 months. No bleeding
episodes were registered in patients who never presented
with Trc < 50 × 109/L. No patients developed severe leu-
cocytopenia in the absence of chemotherapy administra-
tion or complications related to low white blood cell
counts.
Discussion
The present study is to our best knowledge the only con-
temporary series examining the incidence, outcome and
risk factors for development of anaemia and thrombocy-
topenia in patients treated for bone metastases from
prostate cancer. To avoid confounding factors, reversible
events caused by chemotherapy or radioisotope toxicity
were not evaluated. Reversibility was determined by ret-
rospective chart review. Beyond general limitations of
retrospective studies, which might contain hidden
sources of bias, one should be aware of the limited patient
number and thus statistical power . W e can not exclude
the possibility that a larger study could have identified
factors predicting for episodes with Hb < 10 g/dL. How-
ever, the data are derived from a representative unse-
lected patient population, actually including all men with
bone metastases from prostate cancer in a well defined
geographical region. Therefore, it is likely that our find-
ings apply to many men with bone metastases from pros-Nieder et al. BMC Cancer 2010, 10:284
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tate cancer treated outside of clinical trials by practicing
oncologists. We had to arbitrarily define anaemia and
thrombocytopenia. Other cut-off values might have been
possible, but we decided to consider the probability for
red blood cell transfusion and risk of bleeding when
choosing Hb < 10 g/dL and Trc < 50 × 109/L. All relevant
clinical events were captured when applying these cut-off
values. Geenen et al. have previously shown that the
white blood cell system did not seem to be affected in
patients with metastatic prostate cancer [5]. The present
study confirms this result.
Treatment was individualised, taking into account age,
organ function, performance status, symptoms etc. The
majority of patients (57%) received taxotere after diagno-
Table 1: Baseline characteristics of 51 men with prostate cancer and bone metastases
Parameter All 51 patients 20 patients with bone 
metastases at first cancer 
diagnosis
31 patients with metachronous 
diagnosis of bone metastases
Median age, range (years)* 67, 56-86 64.5, 57-79 73, 56-86
Median age at first cancer diagnosis 66, 53-80 64.5, 57-79 68, 53-80
Median interval, range (months) 18, 0-159 0 46, 5-159
Median PSA, range (μg/L)* 51, 3.9-10,302 339, 42-10,302 21, 3.9-727
Median Hb, range (g/dL)* 13.6, 10.2-16.8 13.9, 10.9-16.8 13.4, 10.2-15.2
Median Trc, range (×109/L)* 218, 137-447 295, 137-435 198, 143-447
Gleason score <7, 7, >7** 6, 9, 23
16%, 24%, 61%
2, 4, 9
13%, 27%, 60%
4, 5, 14
17%, 22%, 61%
Other distant metastases 17
33%
6
30%
11
35%
≤10 bone metastases, >10, 
superscan
21, 25, 5
41%, 49%, 10%
5, 11, 4
20%, 55%, 20%
16, 14, 1
52%, 45%, 3%
Initial prostatectomy or radical 
radiotherapy
8
16%
08
26%
Taxotere treatment 29
57%
12
60%
17
55%
Zoledronic acid treatment 41
80%
17
85%
24
77%
Radioisotope treatment 8
16%
5
25%
3
10%
Median follow-up of living patients, 
range (months)
26, 9-84 31, 12-84 22, 9-67
* when diagnosed with bone metastases
** unknown in 5 patients with synchronous and 8 patients with metachronous diagnosis
PSA: prostate-specific antigen, Hb: haemoglobin, Trc: thrombocytesNieder et al. BMC Cancer 2010, 10:284
http://www.biomedcentral.com/1471-2407/10/284
Page 4 of 6
sis of bone metastases and some patients also had sec-
ond-line treatment with mitoxantrone. Administration of
chemotherapy significantly influenced survival. The 2-
year rate was 68% in chemotherapy-treated patients ver-
sus 41% in others. This difference is only partially attrib-
utable to treatment as this was a retrospective study
where several sources of bias influenced the choice of
treatment. Survival in most patients was 2-3 years, but 4
patients were alive more than 5 years after the detection
of bone metastases.
It should also be noticed that androgen deprivation
therapy might result in declining Hb, e.g., mean reduc-
tion by 1.1 g/dL in the study by Curtis et al. [6]. Beer et al.
observed a mean decline of 0.54 g/dL 3 months after
starting androgen deprivation therapy [7]. However, the
mean level increased in patients with baseline level < 12
g/dL. A decline after 3 months was associated indepen-
Figure 1 Kaplan-Meier estimates of overall survival in 20 patients 
with bone metastases from prostate cancer, which were present 
at first cancer diagnosis, versus 31 patients who developed me-
tachronous bone metastases during the course of disease, p = 
0.6.
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Table 2: Outcome in all 5 patients who developed thrombocyte (Trc) count < 50 × 109/L after diagnosis of bone metastases
Patient nr. Presentation Minimum 
Trc count
Time from bone metastases
to Trc < 50 × 109/L
Previous systemic 
therapy
Outcome after 
Trc < 50 × 109/L
1 Synchronous 15 × 109/L 18 months END, ZA, TAX, MITO Died after 4 weeks, cause 
unknown
2 Synchronous 19 × 109/L 16 months END, ZA, TAX Died from haematuria and 
kidney failure after 8 
weeks
3 Synchronous 20 × 109/L 27 months END, ZA, TAX Developed subdural 
haematoma but died from 
sepsis after 4 months
4 Synchronous 26 × 109/L 4 months END, ZA Died from surgery 
complications (for pathol. 
fracture) after 3 weeks
5M e t a c h r o n o u s 3 0  ×  1 0 9/L 9 months END, ZA Died from subdural 
haematoma after 3 weeks
END: endocrine therapy, ZA: zoledronic acid, TAX: taxotere, MITO: mitoxantrone
Figure 2 Kaplan-Meier estimates of time to haemoglobin <10 g/
dL in 20 patients with bone metastases from prostate cancer, 
which were present at first cancer diagnosis, versus 31 patients 
who developed metachronous bone metastases during the 
course of disease, p = 0.4.
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dently with shorter survival and progression-free sur-
vival. Already in a previous study, the same group had
described an association between anaemia and shorter
survival in men with newly diagnosed metastatic prostate
cancer [8]. These recent results confirm established prog-
nostic models such as the one developed by Halabi et al.,
which includes, e.g., Hb, alkaline phosphatase, lactate
dehydrogenase and PSA [9]. Because the focus of the
present study was on haematological events, detailed
analyses of all prognostic factors for survival including
alkaline phosphatase and lactate dehydrogenase were not
performed. Other authors demonstrated that patients
with lower Hb had more advanced disease on bone scan
[10]. The time to development of bone metastases (syn-
chronous versus metachronous presentation) and the
number of foci on isotope bone scan had no influence on
any outcome in the present study. The same holds true
for age and distant metastases at non-skeletal sites. While
Hb at the time of bone metastases detection was not sig-
nificant when using the median value as cut-off, an asso-
ciation of Hb ≤ 12.0 g/dL and short survival might be
present.
A large number of patients (49%) experienced episodes
with Hb < 10 g/dL unexplained by chemotherapy and
radioisotope toxicity, but reflecting disease progression.
Sixty percent of patients with Hb < 10 g/dL required red
blood cell transfusion (29% of all patients in the study). In
a previous study, only 10% of patients became anaemic
and 7.5% received red blood cell transfusion, but that
study was limited to the final year of life and largely to the
pre-taxotere era [4]. Notably the decision to transfuse
and timing is somewhat subjective and varies from physi-
cian to physician. It should also be noted that we did not
administer erythropoiesis stimulating agents, which
might reduce the need for transfusion, given the debate
around these agents and recent recommendations [11-
13]. Median survival from Hb < 10 g/dL was 5.4 months.
Thus, this factor predicts when the disease reaches a crit-
ical point where the remaining life time is very limited.
No risk factors for development of Hb < 10 g/dL could be
identified. Five patients (10%) developed episodes with
Trc < 50 × 109/L. All of these had previously experienced
Hb < 10 g/dL and received red blood cell transfusion.
Thus, 5 of 15 patients (33%) who had required transfu-
sion also developed severe thrombocytopenia. Survival
after detection of severe thrombocytopenia was short,
ranging from 3 weeks to 4 months. Complications such as
haematuria, subdural haematoma and the inability to
recover from emergency surgery were among the causes
of death.
Conclusions
Declining bone marrow function continues to be a com-
mon event during the course of prostate cancer with skel-
etal metastases. It contributes significantly to morbidity
and mortality and poses challenges to those involved in
palliative care for these patients. The current survival fig-
ures after detection of Hb < 10 g/dL and Trc < 50 × 109/L
should be regarded as initial estimates, which need to be
confirmed in larger studies.
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Figure 3 Kaplan-Meier estimate of overall survival after detec-
tion of haemoglobin <10 g/dL in 25 patients.
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Figure 4 Kaplan-Meier estimates of overall survival from first di-
agnosis of bone metastases in 25 patients who developed hae-
moglobin <10 g/dL during follow-up versus 26 patients who 
maintained higher haemoglobin levels, p = 0.01.
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